Company
Nuformix plc
Headquarters: Cambridge, United Kingdom
Employees: 5
Market Cap
£2.6 Million
GBP as of Jan. 1, 2024
US$3.3 Million
Nuformix plc Categories
United Kingdom Healthcare BiotechnologyUnited Kingdom Healthcare United Kingdom Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $461.52 B |
| Vertex Pharmaceuticals Incorporated | $107.23 B |
| Regeneron Pharmaceuticals, Inc. | $100.01 B |
| CSL Limited | $94.74 B |
| Marinomed Biotech AG | $73.23 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Detailed Description
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. Its lead programs include NXP001, which is in Phase 1-ready stage for oncology supportive care; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. The company is also developing NXP004, which is in the research Phase for treating oncology. It also has an option agreement with Oxilio Ltd. for developing and exploiting NXP001 for the treatment of cancer. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Top 1-year algo backtest: +313.24%
$10,000 in May 2023 would now be $41,324 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Nuformix plc has the following listings and related stock indices.
Stock: LSE: NFX wb_incandescent